Treatment of Multiple Sclerosis with the Interferon- s: Comparative Risks and Benefits

Author： Herndon R.M.  

Publisher： Adis International

ISSN： 1173-8804

Source： BioDrugs, Vol.10, Iss.6, 1998-12, pp. : 463-470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Appropriate Use of Interferon Beta-1a in Multiple Sclerosis

By Jacobs L.   Brownscheidle C.M.  

BioDrugs, Vol. 11, Iss. 3, 1999-03 ,pp. : 155-163

Adis International

Access to resources Recommend Favorite

Spotlight on Subcutaneous Recombinant Interferon- -1a (Rebif ® ) in Relapsing-Remitting Multiple Sclerosis

By Murdoch David   Lyseng-Williamson Katherine A.  

BioDrugs, Vol. 19, Iss. 5, 2005-01 ,pp. : 323-325

Adis International

Access to resources Recommend Favorite

Spotlight on Interferon- -1b in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

By Paul L. McCormack   Lesley J. Scott  

BioDrugs, Vol. 18, Iss. 5, 2004-01 ,pp. : 343-347

Adis International

Access to resources Recommend Favorite

Comparative efficacy of switching to natalizumab in active multiple sclerosis

By  

Annals Of Clinical And Translational Neurology, Vol. 2, Iss. 4, 2015-04 ,pp. : 373-387

John Wiley & Sons Inc

Access to resources Recommend Favorite

Recombinant Interferon- -1a: A Review of its Therapeutic Efficacy in Relapsing-Remitting Multiple Sclerosis

By Wagstaff A.J.   Goa K.L.  

BioDrugs, Vol. 10, Iss. 6, 1998-12 ,pp. : 471-494

Adis International

Access to resources Recommend Favorite